A class of drugs built for diabetes has quietly become the largest pharmacological intervention in modern weight management. The next decade will decide whether that story ends in medicine — or in marketing.
GLP-1 
Tirzepatide 
Semaglutide 
Peptides 
Longevity 
Peptides The Telehealth Economy No stories in that topic yet — showing everything.
Ten years of published data. Hundreds of thousands of patient-years of exposure. And yet the questions that matter most to the people on these drugs — what happens to muscle, to bone density, to the brain, to the hunger set point when you stop — have not been answered by anyone with an incentive to ask them. This is a reader's map of what we have, what we don't, and what the next decade of evidence needs to look like.
Begin reading →Five editorial pillars. One anchor story, three headlines apiece.
One essay, three studies worth your time, and the week in metabolic medicine. Written by our editors. 5-minute read. No sponsors in the editorial — ever.
n = 1,247 · Fielded Feb 4 – Mar 12, 2026 · Online panel, 48-state recruit, stratified by drug + dose
Methodology →Physicians, scientists, and reporters on the Wellness Wire bench.
“I write the pieces I wish I could have read when my own patients started asking about these drugs. The goal is mechanism without the hype — and disclosure without the lecture.”